The global gene editing market size accounted for USD 9.30 billion in 2024, grew to USD 10.77 billion in 2025 and is projected to surpass around USD 40.10 billion by 2034, representing a healthy CAGR of 15.73% between 2024 and 2034. The North America gene editing market size is calculated at USD 4.56 billion in 2024 and is expected to grow at a fastest CAGR of 15.84% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Gene Editing Market
5.1. COVID-19 Landscape: Gene Editing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Gene Editing Market, By Product & Services
8.1. Gene Editing Market, by Product & Services, 2024-2034
8.1.1. Reagents & Consumables
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Software & Systems
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Services
8.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Gene Editing Market, By Technology
9.1. Gene Editing Market, by Technology, 2024-2034
9.1.1. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Transcription Activator-Like Effector Nuclease (TALEN)
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Zinc Finger Nuclease (ZFN)
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Antisense
9.1.4.1. Market Revenue and Forecast (2021-2034)
9.1.5. Other technologies
9.1.5.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Gene Editing Market, By Application
10.1. Gene Editing Market, by Application, 2024-2034
10.1.1. Cell Line Engineering
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Genetic Engineering
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Drug Discovery & Development
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Other Applications
10.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Gene Editing Market, By End-user
11.1. Gene Editing Market, by End-user, 2024-2034
11.1.1. Pharmaceutical and Biotechnology Companies
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Academic and Research Institutes
11.1.2.1. Market Revenue and Forecast (2021-2034)
Chapter 12. Global Gene Editing Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.1.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.4. Market Revenue and Forecast, by End-user (2021-2034)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.1.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.5.4. Market Revenue and Forecast, by End-user (2021-2034)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.1.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.1.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.1.6.4. Market Revenue and Forecast, by End-user (2021-2034)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.2.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.4. Market Revenue and Forecast, by End-user (2021-2034)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.2.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.5.4. Market Revenue and Forecast, by End-user (2021-2034)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.2.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.6.4. Market Revenue and Forecast, by End-user (2021-2034)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.2.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.7.4. Market Revenue and Forecast, by End-user (2021-2034)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.2.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.2.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.2.8.4. Market Revenue and Forecast, by End-user (2021-2034)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.3.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.4. Market Revenue and Forecast, by End-user (2021-2034)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.3.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.5.4. Market Revenue and Forecast, by End-user (2021-2034)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.3.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.6.4. Market Revenue and Forecast, by End-user (2021-2034)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.3.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.7.4. Market Revenue and Forecast, by End-user (2021-2034)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.3.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.3.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.3.8.4. Market Revenue and Forecast, by End-user (2021-2034)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.4.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.4. Market Revenue and Forecast, by End-user (2021-2034)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.4.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.5.4. Market Revenue and Forecast, by End-user (2021-2034)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.4.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.6.4. Market Revenue and Forecast, by End-user (2021-2034)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.4.7.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.7.4. Market Revenue and Forecast, by End-user (2021-2034)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.4.8.2. Market Revenue and Forecast, by Technology (2021-2034)
12.4.8.3. Market Revenue and Forecast, by Application (2021-2034)
12.4.8.4. Market Revenue and Forecast, by End-user (2021-2034)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.4. Market Revenue and Forecast, by End-user (2021-2034)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.5.5.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.5.4. Market Revenue and Forecast, by End-user (2021-2034)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product & Services (2021-2034)
12.5.6.2. Market Revenue and Forecast, by Technology (2021-2034)
12.5.6.3. Market Revenue and Forecast, by Application (2021-2034)
12.5.6.4. Market Revenue and Forecast, by End-user (2021-2034)
Chapter 13. Company Profiles
13.1. Beren Therapeutics
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Agilent Technologies
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Creative Biogene
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Thermo Fisher-Scientific
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Synthego
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Integrated DNA Technologie
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Bean Therapeutics
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Intellia Therapeutics
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Lonza
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Horizon Discovery Group plc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample